CellaVision AB (publ) (STO:CEVI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 3.57B -12.1% |
| Revenue (ttm) | 758.97M +4.9% |
| Net Income | 153.08M +8.8% |
| EPS | 6.42 +8.8% |
| Shares Out | 23.85M |
| PE Ratio | 23.34 |
| Forward PE | 20.51 |
| Dividend | 2.75 (1.82%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 34,802 |
| Average Volume | 18,750 |
| Open | 149.60 |
| Previous Close | 149.80 |
| Day's Range | 148.60 - 151.40 |
| 52-Week Range | 139.20 - 208.00 |
| Beta | 1.12 |
| RSI | 49.23 |
| Earnings Date | Apr 24, 2026 |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox... [Read more]
Financial Performance
In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.
Financial StatementsNews
3 Scandinavian Companies With Strong Margin Growth
According to the All-in-One Screener, a Premium feature of GuruFocus, three Scandinavian companies with strong margin growth as of Monday are CellaVision AB (OSTO:CEVI), Fenix Outdoor International Lt...